Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Navidea Biopharma (NAVB) Misses Q1 EPS by 3c, Revenues Miss
May 11, 2021 4:42 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q1 EPS of ($0.11), $0.03 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $123.74 thousand versus the consensus estimate of $600 thousand.
First Quarter 2021 Highlights and Subsequent Events
Submitted a formal Type B Meeting Request to the U.S. Food and Drug Administration (FDA). The FDA granted the Type B Meeting and reviewed the formal briefing documents Navidea submitted containing results from the NAV3-31 Phase 2B study and the proposed Phase 3 design and protocol. Following the feedback received from the FDA at the end of March... More